The key near-term catalyst is QUELL-CV topline data expected in Q4 2026, which will inform dose selection and provide the first proof-of-concept readout for BGE-102 in cardiovascular risk. QUELL-DME data in H2 2027 is a longer-term catalyst. The cash runway through 2029 removes near-term financing risk.
Drug in focus
BIOA drug pipeline →BGE-102
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.
- Next catalyst
- None dated
What to watchThe QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.
Price Chart
Executive Summary
The company completed enrollment in the QUELL-CV Phase 2 cardiovascular trial with topline data expected in Q4 2026, and dosed the first patient in the QUELL-DME Phase 2 diabetic macular edema trial. Cash and marketable securities stood at $352.3M, sufficient through 2029.
Key Financial Metrics
Key Facts
- Net loss of $33.5M for Q3 2026, compared to $20.2M in Q3 2025
- Collaboration revenue of $0.3M, down from $2.1M a year ago
- R&D expenses of $30.2M, up from $18.5M in Q3 2025
- QUELL-CV Phase 2 trial completed enrollment; topline data expected Q4 2026
- First participant dosed in QUELL-DME Phase 2 trial; topline results expected H2 2027
- Cash, cash equivalents and marketable securities of $352.3M as of September 30, 2026
- APJ agonist program IND on track for year-end 2026
- Deep Origin collaboration reached first milestone with validated hits
Financial Impact
Net loss widened by $13.3M year-over-year to $33.5M; EPS of $0.73 loss vs $0.63 consensus; cash burn rate increased as R&D spending rose 63%
Risk Factors
- QUELL-CV Phase 2 data may fail to show adequate dose-response or biomarker improvement
- QUELL-DME Phase 2 trial carries execution risk and results are not expected until H2 2027
- Net loss continues to widen as R&D spending increases with clinical trial activity
- Collaboration revenue declined significantly due to a cumulative catch-up adjustment in the Novartis agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-450008 |
| Document: bioa-20261105.htm | 0001193125-26-450008 |
| Document: 0001193125-26-450008-index-headers.html | 0001193125-26-450008 |
| Document: 0001193125-26-450008-index.html | 0001193125-26-450008 |
| Document: 0001193125-26-450008.txt | 0001193125-26-450008 |
| 8-K Data (Synthetic) | 0001193125-26-450008 |
Track record
11 reports on BIOA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers